{"id":70256,"date":"2026-07-20T12:06:55","date_gmt":"2026-07-20T04:06:55","guid":{"rendered":"https:\/\/flcube.com\/?p=70256"},"modified":"2026-07-20T12:06:56","modified_gmt":"2026-07-20T04:06:56","slug":"wepon-medical-secures-fda-clinical-approval-for-wp107-huperzine-a-oral-solution-in-healthy-volunteers-following-nmpa-clearance-for-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70256","title":{"rendered":"Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Wepon Medical Holding Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002082:SHE\">SHE: 002082<\/a>) announced that <strong>WP107 (Huperzine A Oral Solution)<\/strong> has received <strong>clinical approval from the U.S. Food and Drug Administration (FDA)<\/strong> to conduct a <strong>multiple-dose escalation trial in healthy volunteers<\/strong>. This marks a significant milestone following the company&#8217;s earlier <strong>clinical approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>myasthenia gravis<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-development-timeline\" class=\"wp-block-heading\">Regulatory Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Jurisdiction<\/th><th>Agency<\/th><th>Approval Type<\/th><th>Indication\/Population<\/th><th>Date<\/th><\/tr><\/thead><tbody><tr><td><strong>China<\/strong><\/td><td>NMPA<\/td><td>Clinical Trial Approval<\/td><td>Myasthenia gravis treatment<\/td><td>Prior to Jul 2026<\/td><\/tr><tr><td><strong>United States<\/strong><\/td><td>FDA<\/td><td>IND Clearance<\/td><td>Multiple-dose escalation in healthy volunteers<\/td><td>20 Jul 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Global<\/td><td>Phase I\/II trials<\/td><td>Myasthenia gravis patients<\/td><td>Expected Q4 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-innovation\" class=\"wp-block-heading\">Drug Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Ingredient:<\/strong> Huperzine A \u2013 acetylcholinesterase inhibitor<\/li>\n\n\n\n<li><strong>Additional Mechanisms:<\/strong> Anti-inflammatory, anti-oxidative stress, and neuroprotective effects<\/li>\n\n\n\n<li><strong>Formulation Innovation:<\/strong> Novel oral solution specifically designed to address <strong>swallowing difficulties<\/strong> commonly experienced by myasthenia gravis patients<\/li>\n\n\n\n<li><strong>Patient-Centric Design:<\/strong> Enhanced medication compliance for <strong>pediatric patients<\/strong> who struggle with solid dosage forms<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Addresses significant unmet clinical needs in a patient population with limited treatment options<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-strategy\" class=\"wp-block-heading\">Clinical Development Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Strategy<\/th><\/tr><\/thead><tbody><tr><td><strong>Initial Focus<\/strong><\/td><td>Myasthenia gravis \u2013 rare autoimmune neuromuscular disorder<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Both adult and pediatric patients with swallowing difficulties<\/td><\/tr><tr><td><strong>Competitive Advantage<\/strong><\/td><td>First oral solution formulation of Huperzine A optimized for myasthenia gravis<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>FDA approval enables U.S. clinical development pathway<\/td><\/tr><tr><td><strong>Development Pathway<\/strong><\/td><td>Healthy volunteer safety \u2192 patient efficacy trials \u2192 global regulatory submissions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-amp-unmet-needs\" class=\"wp-block-heading\">Market Opportunity &amp; Unmet Needs<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Myasthenia Gravis Prevalence:<\/strong> Estimated 36,000-60,000 patients in the U.S. and 200,000+ globally<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Current therapies include acetylcholinesterase inhibitors (pyridostigmine), immunosuppressants, and biologics, but many patients experience inadequate symptom control or significant side effects<\/li>\n\n\n\n<li><strong>Swallowing Challenges:<\/strong> Up to 85% of myasthenia gravis patients report dysphagia (swallowing difficulties), making solid oral formulations problematic<\/li>\n\n\n\n<li><strong>Pediatric Considerations:<\/strong> Limited age-appropriate formulations available for children with myasthenia gravis<\/li>\n\n\n\n<li><strong>Market Potential:<\/strong> Global myasthenia gravis therapeutics market projected to reach $2.8 billion by 2030, with premium pricing for innovative, patient-friendly formulations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and market opportunities for WP107. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/ST\u4e07\u90a6\uff1a\u5173\u4e8e\u5b50\u516c\u53f8WP107\u836f\u54c1\u591a\u5242\u91cf\u722c\u5761\u4e34\u5e8a\u7814\u7a76\u83b7\u5f97FDA\u8bb8\u53ef\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of ST\u4e07\u90a6\uff1a\u5173\u4e8e\u5b50\u516c\u53f8WP107\u836f\u54c1\u591a\u5242\u91cf\u722c\u5761\u4e34\u5e8a\u7814\u7a76\u83b7\u5f97FDA\u8bb8\u53ef\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-2b7c1cdb-38a2-4813-8936-8693aeef7cdf\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/ST\u4e07\u90a6\uff1a\u5173\u4e8e\u5b50\u516c\u53f8WP107\u836f\u54c1\u591a\u5242\u91cf\u722c\u5761\u4e34\u5e8a\u7814\u7a76\u83b7\u5f97FDA\u8bb8\u53ef\u7684\u516c\u544a.pdf\">ST\u4e07\u90a6\uff1a\u5173\u4e8e\u5b50\u516c\u53f8WP107\u836f\u54c1\u591a\u5242\u91cf\u722c\u5761\u4e34\u5e8a\u7814\u7a76\u83b7\u5f97FDA\u8bb8\u53ef\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/ST\u4e07\u90a6\uff1a\u5173\u4e8e\u5b50\u516c\u53f8WP107\u836f\u54c1\u591a\u5242\u91cf\u722c\u5761\u4e34\u5e8a\u7814\u7a76\u83b7\u5f97FDA\u8bb8\u53ef\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2b7c1cdb-38a2-4813-8936-8693aeef7cdf\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,1431,2771],"class_list":["post-70256","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-she-002082","tag-wepon-medical-holding"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution) has received clinical approval from the U.S. Food and Drug Administration (FDA) to conduct a multiple-dose escalation trial in healthy volunteers. This marks a significant milestone following the company&#039;s earlier clinical approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of myasthenia gravis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70256\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis\" \/>\n<meta property=\"og:description\" content=\"Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution) has received clinical approval from the U.S. Food and Drug Administration (FDA) to conduct a multiple-dose escalation trial in healthy volunteers. This marks a significant milestone following the company&#039;s earlier clinical approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of myasthenia gravis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70256\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T04:06:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T04:06:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70256#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70256\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis\",\"datePublished\":\"2026-07-20T04:06:55+00:00\",\"dateModified\":\"2026-07-20T04:06:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70256\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"SHE: 002082\",\"Wepon Medical Holding\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70256#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70256\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70256\",\"name\":\"Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-20T04:06:55+00:00\",\"dateModified\":\"2026-07-20T04:06:56+00:00\",\"description\":\"Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution) has received clinical approval from the U.S. Food and Drug Administration (FDA) to conduct a multiple-dose escalation trial in healthy volunteers. This marks a significant milestone following the company's earlier clinical approval from China's National Medical Products Administration (NMPA) for the treatment of myasthenia gravis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70256#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70256\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70256#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry","description":"Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution) has received clinical approval from the U.S. Food and Drug Administration (FDA) to conduct a multiple-dose escalation trial in healthy volunteers. This marks a significant milestone following the company's earlier clinical approval from China's National Medical Products Administration (NMPA) for the treatment of myasthenia gravis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70256","og_locale":"en_US","og_type":"article","og_title":"Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis","og_description":"Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution) has received clinical approval from the U.S. Food and Drug Administration (FDA) to conduct a multiple-dose escalation trial in healthy volunteers. This marks a significant milestone following the company's earlier clinical approval from China's National Medical Products Administration (NMPA) for the treatment of myasthenia gravis.","og_url":"https:\/\/flcube.com\/?p=70256","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-20T04:06:55+00:00","article_modified_time":"2026-07-20T04:06:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70256#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70256"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis","datePublished":"2026-07-20T04:06:55+00:00","dateModified":"2026-07-20T04:06:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70256"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","SHE: 002082","Wepon Medical Holding"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70256#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70256","url":"https:\/\/flcube.com\/?p=70256","name":"Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-20T04:06:55+00:00","dateModified":"2026-07-20T04:06:56+00:00","description":"Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that WP107 (Huperzine A Oral Solution) has received clinical approval from the U.S. Food and Drug Administration (FDA) to conduct a multiple-dose escalation trial in healthy volunteers. This marks a significant milestone following the company's earlier clinical approval from China's National Medical Products Administration (NMPA) for the treatment of myasthenia gravis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70256#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70256"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70256#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Wepon Medical Secures FDA Clinical Approval for WP107 (Huperzine A Oral Solution) in Healthy Volunteers Following NMPA Clearance for Myasthenia Gravis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70256"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70256\/revisions"}],"predecessor-version":[{"id":70258,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70256\/revisions\/70258"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}